| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Product containing xamoterol (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| sympatomimetikumforbindelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Dopamine hydrochloride 40mg/mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Dopamine hydrochloride 80mg/mL injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid 1 % opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid 2 % opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid pellet a 1,9 mg til dental anvendelse |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid 1,15 mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Epinephrine hydrochloride 0.5mg/in |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid 0,85 mg/inch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid 1,15 mg/inch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid 0,82 mg/inch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid 0.5 mg/inch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Epinephrine 1mg/mL |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Epinephrine 0.5mg/mL injection solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| epinephrin 1 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| epinephrin 500 µg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalin 2,0 % opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Adrenaline 5 mg/mL eye solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalin 1,0 % opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid 0,108 mg/cm |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid 0,6 mg pellets |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid 1,7 mg/inch |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| epinephrinhydrochlorid 0,182 mg/cm |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| epinephrinhydrochlorid 0,364 mg/cm |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| noradrenalin 1 mg/ml opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| dexmedetomidinhydrochlorid 100 µg/ml injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Epinephrine 1mg/mL solution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| dopaminhydrochlorid 160 mg/ml opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinhydrochlorid 1 mg/ml injektionsvæske, opløsning, ampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| articainhydrochlorid 40 mg + adrenalin 10 µg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalin 10 µg + lidocainhydrochlorid 20 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalin 20 µg + lidocainhydrochlorid 20 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalin 10 µg + lidocainhydrochlorid 10 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Epinephrine + lidocaine hydrochloride 10mcg/20mg injecti |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Epinephrine + lidocaine hydrochloride 20mcg/20mg |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalin 5 µg + lidocainhydrochlorid 15 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinbitartrat 5 µg + lidocainhydrochlorid 10 mg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Epinephrine bitartrate + lidocaine hydrochloride 10mcg/20mg inj |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Epinephrine bitartrate + lidocaine hydrochloride 20mcg/20mg inj |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinbitartrat 1 % wt/vol + pilocarpinhydrochlorid 1 % wt/vol opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinbitartrat 1 % wt/vol + pilocarpinhydrochlorid 4 % wt/vol opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinbitartrat 1 % + pilocarpinhydrochlorid 6 % wt/vol opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinbitartrat 1 % wt/vol + pilocarpinhydrochlorid 2 % wt/vol opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| dopaminhydrochlorid 400 mg/glucose infusionsvæske, opløsning, hætteglas a 250 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| dopaminhydrochlorid 800 mg glucose infusionsvæske, opløsning, hætteglas a 250 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| sympatomimetikum til respirationssystemet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| epinephrinpræparat til respirationssystemet |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Corbadrine |
Is a |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Bitolterol (substance) |
Is a |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Isometheptene (substance) |
Is a |
True |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Ephedrine (substance) |
Is a |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Phenylpropanolamine (substance) |
Is a |
True |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Iobenguane |
Is a |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Dopamine receptor agonist |
Is a |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Poisoning by sympathomimetic drug |
Causative agent |
True |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
1 |
| Poisoning by epinephrine |
Causative agent |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Product containing dopamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Product containing epinephrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Product containing sympathomimetic (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
1 |
| lidocainhydrochlorid + adrenalin 0,5 %/1:200.000 injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Product containing cocaine and epinephrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| lidocainhydrochlorid + adrenalin 2 %/1:80.000 cylinderampul |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Product containing epinephrine and lidocaine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| cocain 5 % + epinephrin 0,02 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Epinephrine 5 mg/mL and guanethidine monosulfate 30 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| guanethidinmonosulfat 1 % + adrenalin 0,5 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| lidocainhydrochlorid + adrenalin 4 % næsedråber uden konserveringsmiddel |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| lidocainhydrochlorid 1 %/adrenalin 1:200.000 injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| lidocainhydrochlorid 2 %/adrenalin 1:200.000 injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| lidocainhydrochlorid 1,5 %/adrenalin 1:200.000 injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| lidocainhydrochlorid 2 %/adrenalin 1:500.000 injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| lidocainhydrochlorid 2 %/adrenalin 1:100.000 injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| bupivacainhydrochlorid 5 mg + adrenalinbitartrat 0,0091 mg injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| lidocainhydrochlorid 1 %/adrenalin 1:100.000 injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Product containing epinephrine and fluorouracil (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| adrenalinbitartrat + pilocarpinhydrochlorid |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Levosalbutamol-containing product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| dopaminhydrochlorid 40 mg/ml injektionsvæske, opløsning, hætteglas a 100 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| dopaminhydrochlorid 80 mg/ml injektionsvæske, opløsning, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| dopaminhydrochlorid 40 mg/ml injektionsvæske, opløsning, hætteglas a 5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| dopaminhydrochlorid 80 mg/ml injektionsvæske, opløsning, hætteglas a 5 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| lidocain 2 %/adrenalin 1 til 200.000 injektionsvæske, 20 ml hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| dopaminhydrochlorid 40 mg/ml injektionsvæske, opløsning, hætteglas a 10 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| lidocain 1 %/adrenalin 1 til 200.000 injektionsvæske, hætteglas a 20 ml |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| zinksulfat + adrenalin øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Product containing bupivacaine and epinephrine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Adrenaline 2 mg/mL and guanethidine monosulfate 10 mg/mL eye drops |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| guanethidinmonosulfat 0,5 % + adrenalin 0,1 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| guanethidinmonosulfat 0,25 % + adrenalin 0,05 % øjendråber |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| bupivacain + adrenalin 0,25 %/1:200.000 sterilt indpakket injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| bupivacain + adrenalin 0,5 %/1:200.000 sterilt indpakket injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to adrenaline, epinephrine |
Causative agent |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Guanethidine monosulfate+epinephrine |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Adverse reaction to sympathomimetic NOS |
Causative agent |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| bupivacainhydrochlorid + adrenalin 0,5 %/50 µg/10 ml (1:200.000) injektionsvæske, opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| Adrenaline (as adrenaline acid tartrate) 5 microgram/mL and bupivacaine hydrochloride 2.5 mg/mL solution for injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| bupivacainhydrochlorid + adrenalin 0,75 %/1:200.000 injektionsvæske |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| prilocainhydrochlorid 4 %/adrenalin 200.000 injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| bupivacainhydrochlorid 5 mg + adrenalin 5 µg injektionsvæske, opløsning, hætteglas |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
| bupivacainhydrochlorid 7,5 mg + adrenalin 0,005 mg opløsning |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Sympathomimetic agent (substance) |
Inferred relationship |
Some |
|
FHIR